Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Caladrius Bio (NQ: CLBS )

0.5661 +0.0269 (+4.99%)
Streaming Delayed Price Updated: 12:38 PM EDT, Jul 7, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 217,861
Open 0.5350
Bid (Size) 0.5661 (1)
Ask (Size) 0.5699 (3)
Prev. Close 0.5392
Today's Range 0.5350 - 0.5812
52wk Range 0.4019 - 1.540
Shares Outstanding 60,533,064
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Caladrius Biosciences Stops Enrollment In Mid-Stage Heart Disease Study
 
Via Benzinga

Performance

YTD
-36.32%
-36.32%
1 Month
+10.14%
+10.14%
3 Month
-20.60%
-20.60%
6 Month
-43.95%
-43.95%
1 Year
-62.76%
-62.76%

More News

Read More
CALADRIUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBS
From Kahn Swick & Foti, LLC
Via Business Wire
28 Stocks Moving in Thursday's Pre-Market Session
Via Benzinga
Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Via Benzinga
Exposures Product Safety
74 Biggest Movers From Yesterday
Via Benzinga
CLBS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Caladrius Biosciences, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Via Benzinga
48 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Via Benzinga
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
Via Benzinga
Recap: Caladrius Biosciences Q4 Earnings
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Via Benzinga
Earnings Scheduled For March 22, 2022
Via Benzinga
Caladrius Biosciences Earnings Preview
Via Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
21 Stocks Moving in Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
5 Penny Stocks Insiders Are Buying
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Via Benzinga
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.